Syvänne M, Nieminen M S, Frick M H, Kauma H, Majahalme S, Virtanen V, Kesäniemi Y A, Pasternack A, Ehnholm C, Taskinen M R
Department of Medicine, Helsinki University Central Hospital, Helsinki, Findland.
Circulation. 1998 Nov 10;98(19):1993-9. doi: 10.1161/01.cir.98.19.1993.
Lipid-lowering secondary-prevention trials of coronary artery disease (CAD) have implicated triglyceride-rich lipoproteins as the main determinants of angiographic progression after elevated LDL cholesterol levels have been lowered with therapy. The present study focuses on the lipoprotein determinants of angiographic CAD progression in men with low HDL cholesterol concentration as their main baseline lipid abnormality who underwent 32 months of randomized therapy with gemfibrozil or placebo.
Men who had undergone coronary bypass surgery (n=372) completed a randomized, placebo-controlled study with gemfibrozil 1200 mg/d. They were selected primarily for HDL cholesterol levels that corresponded to the lowest third for middle-aged men. Average baseline lipid and lipoprotein levels were serum triglyceride, 1.60; serum cholesterol, 5.17; ultracentrifugally separated LDL cholesterol, 3.43; HDL2 cholesterol, 0.41; and HDL3 cholesterol, 0. 61 mmol/L. In the gemfibrozil group, these levels were reduced on average by 40%, 9%, and 6% or increased by 5% and 9%, respectively. On-trial IDL and LDL triglyceride and cholesterol levels significantly predicted global angiographic progression, taking into account changes in native segments and in bypass grafts. HDL3 but not HDL2 cholesterol concentration was associated with protection against progression, especially focal disease in native coronary lesions. VLDL was the lipoprotein most predictive of new lesions in vein grafts; IDL was also significantly related.
This study expands the previous evidence of the triglyceride-rich lipoproteins, especially IDL, as predictors of angiographic progression of CAD but does not negate the significance of mildly elevated LDL levels. Of the HDL subfractions, only HDL3 was protective in this group of men selected for their low initial HDL levels.
冠状动脉疾病(CAD)的降脂二级预防试验表明,在用药物降低升高的低密度脂蛋白胆固醇(LDL-C)水平后,富含甘油三酯的脂蛋白是血管造影进展的主要决定因素。本研究聚焦于以低高密度脂蛋白胆固醇(HDL-C)浓度为主要基线血脂异常的男性CAD患者血管造影进展的脂蛋白决定因素,这些患者接受了32个月的吉非贝齐或安慰剂随机治疗。
接受冠状动脉搭桥手术的男性(n = 372)完成了一项使用1200 mg/d吉非贝齐的随机、安慰剂对照研究。他们主要因HDL-C水平处于中年男性最低的三分之一而被入选。平均基线血脂和脂蛋白水平为:血清甘油三酯1.60;血清胆固醇5.17;超速离心分离的LDL-C 3.43;HDL2胆固醇0.41;HDL3胆固醇0.61 mmol/L。在吉非贝齐组中,这些水平分别平均降低了40%、9%和6%,或分别升高了5%和9%。考虑到自身血管段和搭桥血管的变化,试验期间的中间密度脂蛋白(IDL)、LDL甘油三酯和胆固醇水平显著预测了整体血管造影进展。HDL3胆固醇浓度而非HDL2胆固醇浓度与预防进展相关,尤其是对自身冠状动脉病变中的局灶性疾病。极低密度脂蛋白(VLDL)是静脉移植物中新病变最具预测性的脂蛋白;IDL也与之显著相关。
本研究扩展了先前关于富含甘油三酯的脂蛋白,尤其是IDL作为CAD血管造影进展预测指标的证据,但并未否定轻度升高的LDL水平的重要性。在HDL亚组分中,只有HDL3对因初始HDL水平低而入选的这组男性具有保护作用。